Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zor ...
January 7, 2025
– Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan’s Pharmaceutical ...Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevun ...
January 6, 2025
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 6, 2025-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...